Tags

Type your tag names separated by a space and hit enter

Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.
Int J Lepr Other Mycobact Dis. 1986 Jun; 54(2):256-67.IJ

Abstract

Sera from 92 patients were tested by the ELISA method for the presence of IgM antibodies to phenolic glycolipid-1 (PGL-1) of Mycobacterium leprae, and of both IgM and IgG antibodies to the whole M. leprae bacillus. All untreated lepromatous patients exhibited high antibody levels in all three assays. A sharp decline of IgM antibodies to PGL-1 and whole M. leprae was observed during the first two years of therapy, while IgG antibodies to whole M. leprae showed a progressive decrease only over a number of years. Low titers of IgM antibodies to PGL-1 and IgG antibodies to whole M. leprae could be detected in about 50% and 75% of patients, respectively, after more than ten years of treatment, with only 15% showing persisting IgM antibodies to the whole bacillus. Antibody levels as measured by the three assays used were correlated with the bacterial index in patients treated for less than four years. In patients treated longer than four years, only IgM antibodies, whether directed to PGL-1 or to whole M. leprae, remained correlated to the bacillary load. Tuberculoid patients exhibited a different antibody pattern, showing a lower frequency (and lower levels) of antibodies of PGL-1 and of IgG antibodies to whole M. leprae than lepromatous patients, and no detectable IgM antibodies to the whole bacillus. IgG antibodies to whole M. leprae were more frequently noted than antibodies to PGL-1, the latter declining more rapidly during therapy.

Authors

Bach MA
No affiliation info available
Wallach D
No affiliation info available
Flageul B
No affiliation info available
Hoffenbach A
No affiliation info available
Cottenot F
No affiliation info available

MeSH

Antibodies, BacterialAntigens, BacterialClofazimineDapsoneDrug Therapy, CombinationEthionamideGlycolipidsHumansImmunoglobulin GImmunoglobulin MLeprostatic AgentsLeprosyLongitudinal StudiesMycobacterium lepraeRifampinTime Factors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

3522769

Citation

Bach, M A., et al. "Antibodies to Phenolic Glycolipid-1 and to Whole Mycobacterium Leprae in Leprosy Patients: Evolution During Therapy." International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, vol. 54, no. 2, 1986, pp. 256-67.
Bach MA, Wallach D, Flageul B, et al. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. Int J Lepr Other Mycobact Dis. 1986;54(2):256-67.
Bach, M. A., Wallach, D., Flageul, B., Hoffenbach, A., & Cottenot, F. (1986). Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 54(2), 256-67.
Bach MA, et al. Antibodies to Phenolic Glycolipid-1 and to Whole Mycobacterium Leprae in Leprosy Patients: Evolution During Therapy. Int J Lepr Other Mycobact Dis. 1986;54(2):256-67. PubMed PMID: 3522769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. AU - Bach,M A, AU - Wallach,D, AU - Flageul,B, AU - Hoffenbach,A, AU - Cottenot,F, PY - 1986/6/1/pubmed PY - 1986/6/1/medline PY - 1986/6/1/entrez SP - 256 EP - 67 JF - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association JO - Int J Lepr Other Mycobact Dis VL - 54 IS - 2 N2 - Sera from 92 patients were tested by the ELISA method for the presence of IgM antibodies to phenolic glycolipid-1 (PGL-1) of Mycobacterium leprae, and of both IgM and IgG antibodies to the whole M. leprae bacillus. All untreated lepromatous patients exhibited high antibody levels in all three assays. A sharp decline of IgM antibodies to PGL-1 and whole M. leprae was observed during the first two years of therapy, while IgG antibodies to whole M. leprae showed a progressive decrease only over a number of years. Low titers of IgM antibodies to PGL-1 and IgG antibodies to whole M. leprae could be detected in about 50% and 75% of patients, respectively, after more than ten years of treatment, with only 15% showing persisting IgM antibodies to the whole bacillus. Antibody levels as measured by the three assays used were correlated with the bacterial index in patients treated for less than four years. In patients treated longer than four years, only IgM antibodies, whether directed to PGL-1 or to whole M. leprae, remained correlated to the bacillary load. Tuberculoid patients exhibited a different antibody pattern, showing a lower frequency (and lower levels) of antibodies of PGL-1 and of IgG antibodies to whole M. leprae than lepromatous patients, and no detectable IgM antibodies to the whole bacillus. IgG antibodies to whole M. leprae were more frequently noted than antibodies to PGL-1, the latter declining more rapidly during therapy. SN - 0148-916X UR - https://www.unboundmedicine.com/medline/citation/3522769/Antibodies_to_phenolic_glycolipid_1_and_to_whole_Mycobacterium_leprae_in_leprosy_patients:_evolution_during_therapy_ DB - PRIME DP - Unbound Medicine ER -